Investigation of gene expression in C2C12 myotubes following simvastatin application and mechanical strain

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 1, 2009, Pages 21-29

  Yu, Ji Guo ^a,b   Sewright, Kimberly ^b   Hubal, Monica J ^b   Liu, Jing Xia ^b   Schwartz, Lawrence M ^b,c   Hoffman, Eric P ^d   Clarkson, Priscilla M ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c Pioneer Valley Life Sciences Institute   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

C2C12 cells; Mechanical strain; Microarray analysis; Myopathy; Statin

Indexed keywords

FLICE INHIBITORY PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MUSCLE PROTEIN; PROTEIN ADRB1; PROTEIN SOCS4; SIMVASTATIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; MEMBRANE TRANSPORT; MOLECULAR MECHANICS; MOUSE; MUSCLE CELL; MYOPATHY; MYOTUBE; NONHUMAN; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 67549105763     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E551     Document Type: Article

References (27)

1. Thompson PD, Clarkson PM, Rosenson RS; The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel: An assessment of statin safety by muscle experts. Am J Cardiol, 2006; 97:69C-76C
2. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR: Lovastatin increases exercise-induced skeletal muscle injury. Metabolism, 1997; 46:1206-1210
3. Bannwarth B: Drug-induced myopathies. Expert Opin Drug Saf, 2002; 1:65-70
4. Sinzinger H, O'Grady J: Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol, 2004; 57:525-528
5. Christopher-Stine L: Statin myopathy: an update. Curr Opin Rheumatol, 2006; 18:647-653
6. Szapary PO, Bloedon LT, Foster GD: Physical activity and its effects on lipids. Curr Cardiol Rep, 2003; 5:488-492
7. Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol, 2006; 291:C1208-1212
8. Lenz TL, Lenz NJ, Faulkner MA: Potential interactions between exercise and drug therapy. Sports Med, 2004; 34:293-306
9. Owczarek J, Jasińska M, Orszulak-Michalak D: Druginduced myopathies. An overview of the possible mechanisms. Pharmacol Rep, 2005; 57:23-34
10. Blanco-Colio LM, Villa A, Ortego M, Hernández-Presa MA, Pascual A, Plaza JJ, Egido J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis, 2002; 161:17-26
11. Erl W: Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis ? Current Drug Targets Cardiovasc Haematol Disord, 2005; 5:135-144
12. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev, 2004; 30:609-641
13. Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, Umbenhauer DR: Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol, 2004; 200:237-250
14. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD: Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol, 2005; 25:2560-2566
15. Yaffe D, Saxel O: Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature, 1977; 270:725-727
16. Burkholder TJ: Permeability of C2C12 myotube membranes is influenced by stretch velocity. Biochem Biophys Res Commun, 2003; 305:266-270
17. Chen YW, Zhao P, Borup R, Hoffman EP: Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol, 2000; 151:1321-1336
18. Seo J, Bakay M, Chen YW, Hilmer S, Shneiderman B, Hoffman EP: Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. Bioinformatics, 2004; 20:2534-2544
19. Bellott AC, Patel KC, Burkholder TJ: Reduction of caveolin-3 expression does not inhibit stretch induced phosphorylation of ERK2 in skeletal muscle myotubes. J Appl Physiol, 2005; 98:1554-1561
20. Urso ML, Scrimgeour AG, Chen YW, Thompson PD, Clarkson PM: Analysis of human skeletal muscle after 48 h immobilization reveals alterations in mRNA and protein for extracellular matrix components. J Appl Physiol, 2006; 101:1136-1148
21. Martin WH 3rd, Coggan AR, Spina RJ, Saffitz JE: Effects of fiber type and training on beta-adrenoceptor density in human skeletal muscle. Am J Physiol, 1989; 257:E736-742
22. Alexander WS: Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol, 2002; 2:410-416
23. Fuentes-Prior P, Salvesen GS: The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J, 2004; 384:201-232
24. Deveraux QL, Takahashi R, Salvesen GS, Reed JC: Xlinked IAP is a direct inhibitor of cell-death proteases. Nature, 1997; 388:300-304
25. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J, 1999; 18:5242-5251
26. Seachrist JL, Loi CM, Evans MG, Criswell KA, Rothwell CE: Roles of exercise and pharmacokinetics in cerivastatininduced skeletal muscle toxicity. Toxicol Sci, 2005; 88:551-561
27. Morikawa S, Murakami T, Yamazaki H, Izumi A, Saito Y, Hamakubo T, Kodama T: Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb, 2005; 12:121-131